Rituximab therapy for factor II inhibitor in a patient with antiphospholipid antibody syndrome

Achuta Kumar Guddati, David J. Kuter

Research output: Contribution to journalArticle

Abstract

Factor II inhibitors have been associated with an increased risk of bleeding. The management of patients with factor II inhibitors has not been adequately described. We describe a patient with an increased bleeding tendency due to factor II inhibitor who was unable to undergo surgery due to her bleeding tendency. The patient was successfully treated with a course of rituximab, which markedly reduced her factor II inhibitor: the factor II level rose from 12 to 61%; prothrombin time decreased from 20 to 14.7s; and partial thromboplastin time (PTT) decreased from 148 to 38.8s. She was able to undergo abdominal surgery without any hemorrhagic complications. This case exemplifies the possibility of treating patients with factor II inhibitors with rituximab therapy.

Original languageEnglish (US)
Pages (from-to)289-291
Number of pages3
JournalBlood Coagulation and Fibrinolysis
Volume25
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Antiphospholipid Syndrome
Hemorrhage
Partial Thromboplastin Time
Prothrombin Time
Therapeutics
Rituximab

Keywords

  • Factor II
  • Hemostasis
  • Inhibitors
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Rituximab therapy for factor II inhibitor in a patient with antiphospholipid antibody syndrome. / Guddati, Achuta Kumar; Kuter, David J.

In: Blood Coagulation and Fibrinolysis, Vol. 25, No. 3, 01.01.2014, p. 289-291.

Research output: Contribution to journalArticle

@article{b30527c34b8f4da08034e4842bbc9860,
title = "Rituximab therapy for factor II inhibitor in a patient with antiphospholipid antibody syndrome",
abstract = "Factor II inhibitors have been associated with an increased risk of bleeding. The management of patients with factor II inhibitors has not been adequately described. We describe a patient with an increased bleeding tendency due to factor II inhibitor who was unable to undergo surgery due to her bleeding tendency. The patient was successfully treated with a course of rituximab, which markedly reduced her factor II inhibitor: the factor II level rose from 12 to 61{\%}; prothrombin time decreased from 20 to 14.7s; and partial thromboplastin time (PTT) decreased from 148 to 38.8s. She was able to undergo abdominal surgery without any hemorrhagic complications. This case exemplifies the possibility of treating patients with factor II inhibitors with rituximab therapy.",
keywords = "Factor II, Hemostasis, Inhibitors, Rituximab",
author = "Guddati, {Achuta Kumar} and Kuter, {David J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MBC.0000000000000072",
language = "English (US)",
volume = "25",
pages = "289--291",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Rituximab therapy for factor II inhibitor in a patient with antiphospholipid antibody syndrome

AU - Guddati, Achuta Kumar

AU - Kuter, David J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Factor II inhibitors have been associated with an increased risk of bleeding. The management of patients with factor II inhibitors has not been adequately described. We describe a patient with an increased bleeding tendency due to factor II inhibitor who was unable to undergo surgery due to her bleeding tendency. The patient was successfully treated with a course of rituximab, which markedly reduced her factor II inhibitor: the factor II level rose from 12 to 61%; prothrombin time decreased from 20 to 14.7s; and partial thromboplastin time (PTT) decreased from 148 to 38.8s. She was able to undergo abdominal surgery without any hemorrhagic complications. This case exemplifies the possibility of treating patients with factor II inhibitors with rituximab therapy.

AB - Factor II inhibitors have been associated with an increased risk of bleeding. The management of patients with factor II inhibitors has not been adequately described. We describe a patient with an increased bleeding tendency due to factor II inhibitor who was unable to undergo surgery due to her bleeding tendency. The patient was successfully treated with a course of rituximab, which markedly reduced her factor II inhibitor: the factor II level rose from 12 to 61%; prothrombin time decreased from 20 to 14.7s; and partial thromboplastin time (PTT) decreased from 148 to 38.8s. She was able to undergo abdominal surgery without any hemorrhagic complications. This case exemplifies the possibility of treating patients with factor II inhibitors with rituximab therapy.

KW - Factor II

KW - Hemostasis

KW - Inhibitors

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84897573498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897573498&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000072

DO - 10.1097/MBC.0000000000000072

M3 - Article

C2 - 24448153

AN - SCOPUS:84897573498

VL - 25

SP - 289

EP - 291

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 3

ER -